13th Annual Proteins and Antibodies Congress

Memo

Over 80 case studies, presentations, panel debates and roundtable discussions focused on the key issues in protein and antibody engineering, bispecifics discovery, biotherapeutics development and bioanalysis, as well as the latest insights into production and manufacturing. View Agenda: https://bit.ly/2MU7dBq 27 April 2019 – Day One (Kick-Off Sessions)• Protein Engineering, Expression, Design and Selection• Bioanalysis: Characterisation, Stability Testing And Formulation Development• Biotherapeutics: Discovery and Development – Oncology and Immuno-Oncology 28 April 2020 – Day Two• Antibody Engineering, Screening, Design, Development• ADC Engineering, Bioconjugates and Fusion Proteins• Biotherapeutics: Discovery and Development – Oncology and Immuno-Oncology 29 April 2020 – Day Three• Antibody Engineering, Development and Generation (Part 1) and Biotherapeutics: Discovery and Development–Non-Oncology Indications (Part 2)• Bioanalysis: PKPD and Manufacturing• Biotherapeutics: Discovery and Development – Non-Oncology Indications PLUS:• Roundtable and Panel Discussions• Pre-Event Webinars On Monday April 27, 2020 at 8:00 am (ends Wednesday April 29, 2020 at 6:00 pm) Price: General Admission: GBP 520.00 URLs: Twitter: https://go.evvnt.com/545898-2?pid=5569 LinkedIn: https://go.evvnt.com/545898-3?pid=5569 Speakers: Tristan Vaughan, Vice President R&D, Antibody Discovery and Protein Engineering, AstraZeneca, Stanislas Blein, Vice President, Head of Antibody Engineering, Glenmark Pharmaceuticals, John McCafferty, Chief Executive Officer, IONTAS Pharmaceuticals, Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma, Andrew Porter, Chief Technology Officer and Professor of Medical Biotechnology, Elasmogen and University of Aberdeen Venue details: Novotel London West, 1 Shortlands, Hammersmith International Ctre, Hammersmith, London, W6 8DR, United Kingdom